Figure 7
- ID
- ZDB-FIG-240405-63
- Publication
- Zhou et al., 2024 - Activating SRC/MAPK signaling via 5-HT1A receptor contributes to the effect of vilazodone on improving thrombocytopenia
- Other Figures
- All Figure Page
- Back to All Figure Page
VLZ induces megakaryocyte (MK) maturation and differentiation by activating the SRC/RAS/MEK/ERK signaling pathway. (a-h) The expression of SRC, RAS, MEK, ERK, NF-E2, EGR1, FOS, and RUNX1 were detected by western blot after Meg-01 cells were treated with VLZ (2.5, 5, and 10 μM) for 5 days (n=3 per group). (i, j) Immunofluorescence analysis of the expression of NF-E2 and RUNX1 in Meg-01 cells after VLZ (2.5, 5, and 10 μM) intervention for 5 days. Cells were stained with DAPI for nuclei (blue) and antibodies for NF-E2 (green). Bars represent 100 μm. (k) Flow cytometry analysis of the percentage of CD41+ CD42b+ complexes surface expression on HEL and Meg-01 cells treated with VLZ (10 μM), SCH772984 (3 μM), and VLZ (10 μM)+SCH772984 (3 μM) treated for 5 days. The histogram shows the percentage of CD41+/CD42b+ cells for each group. The data represent the mean ± SD of three independent experiments. *p≤0.05, **p≤0.01, and ***p≤0.001, ns: no significance, vs the control group. |